PainReform Ltd. Releases 6-K Report: Update on PRF-110 Phase 3 Clinical Trial

Here are the key points extracted from the provided section of the financial report (Form 6-K) for PainReform Ltd.:

1. Report Details:

• Form: 6-K (Report of Foreign Private Issuer)
• Commission File Number: 001-39481
• Filing Date: December 27, 2024
• Reporting Period: For the month of December 2024

2. Company Information:

• Name: PainReform Ltd.
• Address: 65 Yigal Alon St., Tel Aviv 6744316, Israel

3. Annual Report Filing:

• The registrant indicated that it files annual reports under Form 20-F.

4. Press Release:

• A press release titled “PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110” was issued on December 27, 2024. This press release is attached as Exhibit 99.1 and is incorporated by reference.

5. Incorporation by Reference:

• The first three paragraphs of the attached press release (Exhibit 99.1) are incorporated by reference into the Company’s Registration Statements on Form S-8 and Form F-3.

6. Signatory Information:

• The report is signed by Ehud Geller, who is the Executive Chairman of the Board and Interim Chief Executive Officer of PainReform Ltd.

Insights:

• The report is important for stakeholders as it provides an update on a significant clinical trial, which could impact the company’s future prospects and stock performance.
• The filing of Form 20-F indicates that PainReform is compliant with SEC requirements for foreign issuers, providing a level of assurance to investors about regulatory adherence.
• The incorporation of the press release into registration statements suggests that the information is deemed material and relevant for investors and regulatory purposes.